Supplemental Figure S5.

(a) The annual %FVC change rate

(b) Survival rate (%)

Comparison of the effects of the patients prescribed nintedanib (n=20) and those prescribed pirfenidone (n=14) in the non-IPF antifibrotic group.

(a) The annual %FVC change rate / year were compared by the Wilcoxon rank sum test.
(b) Survival estimates were performed using the Kaplan–Meier method and compared by log-rank test.
Abbreviations: %FVC; percentage of forced vital capacity; NS, not significant.